Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model by Victor Sokolov, Victor Sokolov, Tatiana Yakovleva, Robert C. Penland, David W. Boulton, Weifeng Tang

Connect to this object online.

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes by Victor Sokolov, Tatiana Yakovleva, Leonid Stolbov, Robert C. Penland, David Boulton, Joanna Parkinson, Weifeng Tang

Connect to this object online.

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling by Victor Sokolov, Tatiana Yakovleva, Lulu Chu, Weifeng Tang, Peter J. Greasley, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W. Boulton, Robert C. Penland

Connect to this object online.

Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development by Gabriel Helmlinger, Victor Sokolov, Kirill Peskov, Karen M. Hallow, Yuri Kosinsky, Veronika Voronova, Lulu Chu, Tatiana Yakovleva, Ivan Azarov, Daniel Kaschek, Artem Dolgun, Henning Schmidt, David W. Boulton, Robert C. Penland

Connect to this object online.